On 2024, December 5, the CCHFVACIM Executive Committee convened in Brussels at the Residence Palace for a morning of strategic discussions and updates. This pivotal meeting brought project partners together to review progress, address challenges, and outline priorities for the months ahead.
Agenda Highlights
- Project Management and Communication Updates: Progress on dissemination and exploitation strategies, including steps to enhance the project’s visibility.
- Work Package (WP) Updates:
- WP2: Structure and characterization of CCHF antigens.
- WP3: Immunogenicity studies.
- WP4: Animal models.
- WP5: Development of mRNA-based vaccines.
- WP6: Monoclonal antibody development.
- Ethics Discussion: A critical review of ethical considerations across the project’s activities.
- Q&A and Open Discussion: An opportunity for participants to raise concerns and collaborate on strategic next steps.
Key Takeaways and Priorities
- Recent Progress:
- Advancement in vaccine platforms and monoclonal antibody development.
- Strengthened internal collaboration through innovative communication tools.
- Next Steps:
- Distribution of brochures and communication materials at scientific events and on social media channels to engage a broader audience.
- Acceleration of animal model studies to support preclinical trials.
Expected Impact
Funded by Horizon Europe, CCHFVACIM aims to enhance preparedness against the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) by developing innovative vaccines and treatments. This meeting reinforced partner commitments and laid the groundwork for achieving the project’s ambitious objectives.
